Castle Biosciences (NASDAQ:CSTL) Insider Sells 3,294 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,294 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $35.14, for a total transaction of $115,751.16. Following the completion of the sale, the insider directly owned 58,584 shares of the company’s stock, valued at $2,058,641.76. This trade represents a 5.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Down 0.1%

Shares of NASDAQ CSTL traded down $0.02 during trading on Wednesday, reaching $35.48. 559,268 shares of the stock were exchanged, compared to its average volume of 397,261. The business’s 50-day moving average price is $29.56 and its 200 day moving average price is $25.54. Castle Biosciences, Inc. has a twelve month low of $17.72 and a twelve month high of $44.28. The company has a quick ratio of 5.85, a current ratio of 6.04 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -53.76 and a beta of 0.99.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. The business had revenue of $99.86 million during the quarter, compared to analyst estimates of $86.23 million. As a group, equities analysts forecast that Castle Biosciences, Inc. will post -1.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on CSTL. BTIG Research lifted their target price on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Roth Capital began coverage on Castle Biosciences in a report on Wednesday, June 24th. They issued a “buy” rating and a $40.00 price target for the company. Zacks Research lowered Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. Robert W. Baird set a $36.00 price objective on Castle Biosciences in a report on Friday, July 31st. Finally, KeyCorp set a $35.00 target price on Castle Biosciences in a research report on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.00.

Institutional Investors Weigh In On Castle Biosciences

Institutional investors have recently modified their holdings of the stock. Global Retirement Partners LLC acquired a new position in Castle Biosciences in the second quarter worth about $26,000. Quantbot Technologies LP acquired a new stake in Castle Biosciences during the second quarter valued at approximately $62,000. Caitong International Asset Management Co. Ltd raised its stake in Castle Biosciences by 140.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company’s stock valued at $68,000 after buying an additional 1,022 shares in the last quarter. State of Wyoming bought a new position in Castle Biosciences during the 2nd quarter worth approximately $117,000. Finally, Assetmark Inc. lifted its holdings in Castle Biosciences by 9.3% during the 1st quarter. Assetmark Inc. now owns 5,779 shares of the company’s stock worth $142,000 after buying an additional 492 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians make more informed decisions about cancer diagnosis and treatment. Its products use genomic and molecular information to assess disease characteristics, patient risk and likely outcomes.

The company’s portfolio includes DecisionDx-Melanoma, which helps assess the risk of metastasis in patients with cutaneous melanoma; DecisionDx-SCC, which evaluates metastatic risk in certain patients with cutaneous squamous cell carcinoma; and MyPath Melanoma, which assists in distinguishing benign from malignant melanocytic lesions.